July 9, 2020
As part of Dry Eye Awareness month,the Intrepid Eye Society has partnered with the Tear Film & Ocular Surface Society to present “New Therapeutic Approaches and Challenges for the Treatment of Dry Eyes,” 1 hour COPE Pending, taught by David A. Sullivan, MS, PhD, FARVO.
The webinar will take place July 16, 2020, 8:30 p.m. Eastern Time.
Dry eye disease (DED) afflicts hundreds of millions of people throughout the world and is one of the most frequent causes of patient visits to eyecare practitioners, Dr. Sullivan writes in his course description: “DED is a symptomatic disease, characterized by a vicious cycle of hyperosmolarity and tear film instability, which leads to increased ocular surface inflammation, damage and neurosensory abnormalities. Moderate to severe DED is often associated with significant pain, limitations in performing daily activities, reduced vitality, poor general health, and depression.
There is no safe and effective global treatment for DED, and its therapy remains a profound unmet need. A virtual kaleidoscope of new therapeutic approaches has been proposed to treat aqueous- deficient and/or evaporative DED.”
Other Articles to Explore
Dr. Sullivan’s presentation will highlight these approaches, and also address the significant clinical endpoint challenges that serve as barriers to the successful development of potential treatments for DED.
Dr. Sullivan is a Ph.D. graduate of Dartmouth Medical School (Hanover, NH), an Associate Professor in the Department of Ophthalmology at Harvard Medical School and a Senior Scientist at the Schepens Eye Research Institute (SERI; Boston, MA). During the past 37 years, his research has focused on the interrelationships between sex, sex steroids and dry eye disease, as well as on the role of lubricin on the ocular surface.